These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Atrial fibrillation in fracture patients treated with oral bisphosphonates. Abrahamsen B; Eiken P; Brixen K J Intern Med; 2009 May; 265(5):581-92. PubMed ID: 19141097 [TBL] [Abstract][Full Text] [Related]
4. Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study. Coloma PM; de Ridder M; Bezemer I; Herings RM; Gini R; Pecchioli S; Scotti L; Rijnbeek P; Mosseveld M; van der Lei J; Trifirò G; Sturkenboom M; Osteoporos Int; 2016 May; 27(5):1857-67. PubMed ID: 26694594 [TBL] [Abstract][Full Text] [Related]
5. Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis. Rhee CW; Lee J; Oh S; Choi NK; Park BJ Osteoporos Int; 2012 Jan; 23(1):247-54. PubMed ID: 21431993 [TBL] [Abstract][Full Text] [Related]
6. Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures. Lapi F; Cipriani F; Caputi AP; Corrao G; Vaccheri A; Sturkenboom MC; Di Bari M; Gregori D; Carle F; Staniscia T; Vestri A; Brandi M; Fusco V; Campisi G; Mazzaglia G; Osteoporos Int; 2013 Feb; 24(2):697-705. PubMed ID: 22618266 [TBL] [Abstract][Full Text] [Related]
7. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. Sørensen HT; Christensen S; Mehnert F; Pedersen L; Chapurlat RD; Cummings SR; Baron JA BMJ; 2008 Apr; 336(7648):813-6. PubMed ID: 18334527 [TBL] [Abstract][Full Text] [Related]
9. Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study. Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L Calcif Tissue Int; 2010 May; 86(5):335-42. PubMed ID: 20309678 [TBL] [Abstract][Full Text] [Related]
10. Risk of atrial fibrillation with use of oral and intravenous bisphosphonates. Sharma A; Einstein AJ; Vallakati A; Arbab-Zadeh A; Walker MD; Mukherjee D; Homel P; Borer JS; Lichstein E Am J Cardiol; 2014 Jun; 113(11):1815-21. PubMed ID: 24837258 [TBL] [Abstract][Full Text] [Related]
11. Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Bunch TJ; Anderson JL; May HT; Muhlestein JB; Horne BD; Crandall BG; Weiss JP; Lappé DL; Osborn JS; Day JD Am J Cardiol; 2009 Mar; 103(6):824-8. PubMed ID: 19268739 [TBL] [Abstract][Full Text] [Related]
12. Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis. Sharma A; Chatterjee S; Arbab-Zadeh A; Goyal S; Lichstein E; Ghosh J; Aikat S Chest; 2013 Oct; 144(4):1311-1322. PubMed ID: 23722644 [TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Loke YK; Jeevanantham V; Singh S Drug Saf; 2009; 32(3):219-28. PubMed ID: 19338379 [TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. Mak A; Cheung MW; Ho RC; Cheak AA; Lau CS BMC Musculoskelet Disord; 2009 Sep; 10():113. PubMed ID: 19772579 [TBL] [Abstract][Full Text] [Related]
15. Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. Wilkinson GS; Baillargeon J; Kuo YF; Freeman JL; Goodwin JS J Clin Oncol; 2010 Nov; 28(33):4898-905. PubMed ID: 20940190 [TBL] [Abstract][Full Text] [Related]
16. Relationship of Bisphosphonate Therapy and Atrial Fibrillation/Flutter: Outcomes of Sleep Disorders in Older Men (MrOS Sleep) Study. Thadani SR; Ristow B; Blackwell T; Mehra R; Stone KL; Marcus GM; Varosy PD; Cummings SR; Cawthon PM; Chest; 2016 May; 149(5):1173-80. PubMed ID: 26836889 [TBL] [Abstract][Full Text] [Related]
17. Use of alendronate and risk of incident atrial fibrillation in women. Heckbert SR; Li G; Cummings SR; Smith NL; Psaty BM Arch Intern Med; 2008 Apr; 168(8):826-31. PubMed ID: 18443257 [TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate therapy start may transiently increase the risk of tendon rupture in patients with glucocorticoid co-medication: a population-based observational study. Spoendlin J; Meier C; Jick SS; Meier CR Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1116-1123. PubMed ID: 27297005 [TBL] [Abstract][Full Text] [Related]
19. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. Lee J; Youn K; Choi NK; Lee JH; Kang D; Song HJ; Park BJ J Gastroenterol; 2013 Sep; 48(9):1016-22. PubMed ID: 23307040 [TBL] [Abstract][Full Text] [Related]
20. Antipsychotic treatment is associated with risk of atrial fibrillation: A nationwide nested case-control study. Chou RH; Lo LW; Liou YJ; Shu JH; Hsu HC; Liang Y; Huang CC; Huang PH; Lin SJ; Chen JW; Chan WL; Leu HB Int J Cardiol; 2017 Jan; 227():134-140. PubMed ID: 27855291 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]